Seres Therapeutics (NASDAQ:MCRB – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Seres Therapeutics to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership.
Insider and Institutional Ownership
59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Seres Therapeutics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seres Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Seres Therapeutics Competitors | 9834 | 15121 | 45433 | 1587 | 2.54 |
Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 758.59%. As a group, “Biotechnology” companies have a potential upside of 102.54%. Given Seres Therapeutics’ higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than its rivals.
Earnings and Valuation
This table compares Seres Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Seres Therapeutics | $789,000.00 | $5.70 million | -0.40 |
| Seres Therapeutics Competitors | $716.53 million | $12.10 million | -15.00 |
Seres Therapeutics’ rivals have higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Seres Therapeutics has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Seres Therapeutics’ rivals have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.
Profitability
This table compares Seres Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seres Therapeutics | -2,209.55% | -194.42% | -58.15% |
| Seres Therapeutics Competitors | -12,357.18% | -197.96% | -30.56% |
Summary
Seres Therapeutics rivals beat Seres Therapeutics on 8 of the 13 factors compared.
About Seres Therapeutics
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
